HomeAboutRankingsData Sources
© 2026 GeneE
🧬
GeneE
10 sources retrieved · Most recent: April 2026 · Index updated 15 days ago
ⓘGeneE is for informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment.
TUBA3C
tubulin alpha 3c
Chromosome 13 · 13q12.11
NCBI Gene: 7278Ensembl: ENSG00000198033.13HGNC: HGNC:12408UniProt: P0DPH7
87PubMed Papers
20Diseases
86Drugs
0Pathogenic Variants
CLINICAL
FDA Approved Target
DATA QUALITY
✓ Experimental GO Evidence✓ Swiss-Prot Reviewed
microtubule cytoskeletonnucleusciliummitotic cell cyclebreast cancernon-small cell lung carcinomabreast neoplasmbreast carcinoma
✦AI Summary

TUBA3C encodes a testis-specific alpha-tubulin isoform that is a structural constituent of microtubules, particularly important for sperm motility and male fertility 1. The protein functions as part of alpha- and beta-tubulin heterodimers that form microtubule protofilaments, with GTP-binding activity essential for microtubule dynamics. TUBA3C expression is significantly decreased in asthenozoospermia (poor sperm motility), suggesting its critical role in flagellar function 1. Chr13 abnormalities affecting TUBA3C, such as balanced reciprocal translocations involving chromosome 13.1 where TUBA3C is located, have been associated with sperm immotility and abnormal morphology leading to male infertility 2. Genome sequencing studies have identified biallelic missense mutations in TUBA3C in consanguineous families with hereditary male infertility 3. Beyond reproductive function, TUBA3C has been implicated in other cellular processes, with differential expression observed in aging spermatozoa 4, and potential roles in neurodegenerative diseases like Alzheimer's disease through vesicle trafficking mechanisms 5. The gene also shows prognostic significance in hepatocellular carcinoma as part of mitotic cell cycle regulation 6.

Sources cited
1
TUBA3C is decreased in asthenozoospermia and is important for sperm motility
PMID: 24268707
2
Chromosomal abnormalities affecting TUBA3C cause sperm immotility and infertility
PMID: 22125161
3
Biallelic missense mutations in TUBA3C identified in families with hereditary male infertility
PMID: 38073178
4
TUBA3C expression changes with aging in spermatozoa
PMID: 40649876
5
TUBA3C implicated in Alzheimer's disease through vesicle trafficking
PMID: 40338387
6
TUBA3C has prognostic significance in hepatocellular carcinoma
PMID: 40875626
Disease Associationsⓘ20
breast cancerOpen Targets
0.60Moderate
non-small cell lung carcinomaOpen Targets
0.60Moderate
breast neoplasmOpen Targets
0.60Moderate
breast carcinomaOpen Targets
0.60Moderate
neoplasmOpen Targets
0.60Moderate
goutOpen Targets
0.59Moderate
Hodgkins lymphomaOpen Targets
0.58Moderate
multiple myelomaOpen Targets
0.58Moderate
familial Mediterranean feverOpen Targets
0.58Moderate
cervical cancerOpen Targets
0.58Moderate
prostate cancerOpen Targets
0.58Moderate
diffuse large B-cell lymphomaOpen Targets
0.58Moderate
head and neck malignant neoplasiaOpen Targets
0.57Moderate
lymphomaOpen Targets
0.57Moderate
stomach neoplasmOpen Targets
0.57Moderate
prostate neoplasmOpen Targets
0.56Moderate
adenocarcinomaOpen Targets
0.56Moderate
head and neck neoplasiaOpen Targets
0.56Moderate
gastric cancerOpen Targets
0.56Moderate
pancreatic neoplasmOpen Targets
0.55Moderate
Pathogenic Variants
No pathogenic variants reported on ClinVar for this gene.
View on ClinVar ↗
Drug Targets86
AGS-16C3FPhase II
Tubulin disrupting agent
renal cell carcinoma
ANETUMAB RAVTANSINEPhase II
Tubulin inhibitor
malignant pleural mesothelioma
ANG1005Phase II
Tubulin inhibitor
ANVATABART OPADOTINPhase II/III
Tubulin inhibitor
HER2 Positive Breast Carcinoma
APRUTUMAB IXADOTINPhase I
Fibroblast growth factor receptor 2 binding agent
cancer
ASG-5MEPhase I
Choline transporter-like protein 4 binding agent
Malignant Pancreatic Neoplasm
AVE-9633Phase I
Myeloid cell surface antigen CD33 binding agent
myeloid leukemia
AZINTUXIZUMAB VEDOTINPhase I
SLAM family member 7 binding agent
multiple myeloma
BELANTAMAB MAFODOTINApproved
Tumor necrosis factor receptor superfamily member 17 binding agent
multiple myeloma
BIIB-015Phase I
Teratocarcinoma-derived growth factor 1 binding agent
BIVATUZUMAB MERTANSINEUNKNOWN
Tubulin inhibitor
BMS-275183Phase II
Tubulin stabiliser
BRENTUXIMAB VEDOTINApproved
Tubulin inhibitor
CABAZITAXELApproved
Tubulin inhibitor
prostate cancer
CANTUZUMAB MERTANSINEPhase II
Tubulin inhibitor
non-small cell lung carcinoma
CANTUZUMAB RAVTANSINEPhase II
Mucin-1 binding agent
stomach neoplasm
COLCHICINEApproved
Tubulin inhibitor
familial Mediterranean fever
COLTUXIMAB RAVTANSINEPhase II
Tubulin inhibitor
diffuse large B-cell lymphoma
CROLIBULINPhase I/II
Tubulin inhibitor
DAVUNETIDEPhase III
Tubulin stabiliser
Cognitive impairment
DENINTUZUMAB MAFODOTINPhase II
B-lymphocyte antigen CD19 binding agent
diffuse large B-cell lymphoma
DEPATUXIZUMAB MAFODOTINPhase III
Epidermal growth factor receptor erbB1 binding agent
glioblastoma multiforme
DISITAMAB VEDOTINPhase III
Receptor tyrosine-protein kinase erbB-2 binding agent
breast cancer
DOCETAXELApproved
Tubulin inhibitor
DOCETAXEL ANHYDROUSApproved
Tubulin stabiliser
prostate cancer
DOLASTATIN-10Phase II
Tubulin inhibitor
ENAPOTAMAB VEDOTINPhase I/II
Tyrosine-protein kinase receptor UFO binding agent
ENFORTUMAB VEDOTINApproved
Nectin-4 binding agent
EPOTHILONE DPhase II
Tubulin stabiliser
breast cancer
ERIBULINApproved
Tubulin inhibitor
breast cancer
ERIBULIN MESYLATEApproved
Tubulin inhibitor
breast cancer
FOSBRETABULINPhase III
Tubulin disrupting agent
thyroid cancer
FOSBRETABULIN DISODIUMPhase II
Tubulin inhibitor
neuroendocrine carcinoma
FOSBRETABULIN TROMETHAMINEPhase II/III
Tubulin disrupting agent
ovarian cancer
GLEMBATUMUMAB VEDOTINApproved
Transmembrane glycoprotein NMB binding agent
lymphoma
IMGN-388Phase I
Vitronectin receptor alpha binding agent
INDATUXIMAB RAVTANSINEPhase II
Syndecan-1 binding agent
multiple myeloma
INDIBULINPhase II
Tubulin inhibitor
INDUSATUMAB VEDOTINPhase II
Heat-stable enterotoxin receptor binding agent
IXABEPILONEApproved
Tubulin inhibitor
breast cancer
KOS-1584Phase II
Tubulin stabiliser
non-small cell lung carcinoma
LADIRATUZUMAB VEDOTINPhase II
Zinc transporter ZIP6 binding agent
breast cancer
LAROTAXELPhase III
Tubulin stabiliser
urinary bladder carcinoma
LEXIBULINPhase II
Tubulin inhibitor
glioblastoma multiforme
LIFASTUZUMAB VEDOTINPhase II
Sodium-dependent phosphate transport protein 2B binding agent
ovarian cancer
LORVOTUZUMAB MERTANSINEPhase II
Neural cell adhesion molecule 1 binding agent
MECBOTAMAB VEDOTINPhase II
Tyrosine-protein kinase receptor UFO binding agent
ovarian cancer
MILATAXELPhase II
Tubulin inhibitor
MIRVETUXIMAB SORAVTANSINEApproved
Folate receptor alpha binding agent
ovarian cancer
MLN-2704Phase I/II
Glutamate carboxypeptidase II binding agent
prostate cancer
OMBRABULINPhase III
Tubulin inhibitor
sarcoma
PACLITAXELApproved
Tubulin inhibitor
PACLITAXEL DOCOSAHEXAENOIC ACIDPhase III
Tubulin stabiliser
non-small cell lung carcinoma
PACLITAXEL POLIGLUMEXApproved
Tubulin stabiliser
neoplasm
PATUPILONEPhase III
Tubulin stabiliser
PF-06263507Phase I
Tubulin inhibitor
PINATUZUMAB VEDOTINPhase II
CD22 binding agent
diffuse large B-cell lymphoma
PLINABULINPhase III
Tubulin inhibitor
non-small cell lung carcinoma
PLOCABULINPhase II
Tubulin inhibitor
colorectal cancer
POLATUZUMAB VEDOTINApproved
Tubulin inhibitor
diffuse large B-cell lymphoma
PRALUZATAMAB RAVTANSINEPhase II
Tubulin inhibitor
neoplasm
RG-7598Phase I
Fc receptor-like protein 5 binding agent
multiple myeloma
RG-7600Phase I
Tubulin inhibitor
ovarian cancer
RG-7636Phase I
Tubulin inhibitor
melanoma
RG-7841Phase I
Lymphocyte antigen 6E binding agent
SAGOPILONEPhase II
Tubulin stabiliser
breast cancer
SAR-566658Phase II
Tubulin inhibitor
triple-negative breast cancer
SOBLIDOTINPhase II
Tubulin inhibitor
SOFITUZUMAB VEDOTINPhase I
Mucin-16 binding agent
fallopian tube cancer
T-900607Phase II
Tubulin disrupting agent
hepatocellular carcinoma
TELISOTUZUMAB VEDOTINPhase III
Hepatocyte growth factor receptor binding agent
non-small cell lung carcinoma
TISOTUMAB VEDOTINApproved
Coagulation factor III binding agent
cervical cancer
TRASTUZUMAB BOTIDOTINPhase III
Tubulin inhibitor
HER2 Positive Breast Carcinoma
TRASTUZUMAB EMTANSINEApproved
Receptor protein-tyrosine kinase erbB-2 binding agent
TUSAMITAMAB RAVTANSINEPhase III
Carcinoembryonic antigen-related cell adhesion molecule 5 binding agent
non-small cell lung carcinoma
VANDORTUZUMAB VEDOTINPhase I
Metalloreductase STEAP1 binding agent
prostate cancer
VERUBULINPhase II
Tubulin disrupting agent
VINBLASTINEApproved
Tubulin inhibitor
VINBLASTINE SULFATEApproved
Tubulin inhibitor
lymphoma
VINCRISTINEApproved
Tubulin inhibitor
VINCRISTINE SULFATEApproved
Tubulin inhibitor
VINFLUNINEApproved
Tubulin inhibitor
VINFLUNINE DITARTRATEApproved
Tubulin inhibitor
benign urinary system neoplasm
VINORELBINEApproved
Tubulin inhibitor
VINORELBINE TARTRATEApproved
Tubulin inhibitor
VORSETUZUMAB MAFODOTINPhase I
Tubulin inhibitor
renal cell carcinoma
Related Genes
TUBA3EShared pathway100%TUBB8BProtein interaction85%TUBB6Protein interaction83%TUBB2AProtein interaction81%TUBB4BProtein interaction78%TUBA4AShared pathway75%
Tissue Expression6 tissues
Brain
100%
Liver
50%
Bone Marrow
25%
Ovary
25%
Heart
0%
Lung
0%
Gene Interaction Network
Click a node to explore
TUBA3CTUBA3ETUBB8BTUBB6TUBB2ATUBB4BTUBA4A
PROTEIN STRUCTURE
Preparing viewer…
AlphaFoldAI-predicted · UniProt P0DPH7
View on AlphaFold ↗
Constraintⓘ
LOEUFⓘ
0.92LoF Tolerant
pLIⓘ
0.00Tolerant
Observed/Expected LoF0.66 [0.48–0.92]
RankingsWhere TUBA3C stands among ~20K protein-coding genes
  • #5,522of 20,598
    Most Researched87
  • #68of 1,025
    FDA-Approved Drug Targets25 · top 10%
  • #8,503of 17,882
    Most Constrained (LOEUF)0.92
Genes detectedTUBA3C
Sources retrieved10 papers
Response time—
📄 Sources
10▼
1
Age-Associated Proteomic Changes in Human Spermatozoa.
PMID: 40649876
Int J Mol Sci · 2025
1.00
2
Acetylated α-tubulin is reduced in individuals with poor sperm motility.
PMID: 24268707
Fertil Steril · 2014
0.90
3
Identification of Novel Biomarkers Related to Vesicle Trafficking in Alzheimer's Disease Using Bioinformatics Approaches.
PMID: 40338387
Neurochem Res · 2025
0.80
4
Machine learning-based identification of diagnostic and prognostic mitotic cell cycle genes in hepatocellular carcinoma.
PMID: 40875626
PLoS One · 2025
0.70
5
Epigenetic patterns in successful weight loss maintainers: a pilot study.
PMID: 25520250
Int J Obes (Lond) · 2015
0.60